CD19 expression in acute leukemia is not restricted to the cytogenetically aberrant populations

Leukemia and Lymphoma

Volumn 54, Issue 7, 2013, Pages 1517-1520

  Francis, Jawad ^a   Dharmadhikari, Avinash V ^a   Sait, Sheila N J ^a   Deeb, George ^a   Wallace, Paul K ^a   Thompson, James E ^a   Wang, Eunice S ^a   Wetzler, Meir ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Acute myeloid leukemia; CD19; Flow cytometry; Fluorescence in situ hybridization

Indexed keywords

CD19 ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIGEN EXPRESSION; ARTICLE; CLINICAL ARTICLE; CYTOGENETICS; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; KARYOTYPE; LEUKEMIA CELL; PRIORITY JOURNAL;

ANTIGENS, CD19; CHROMOSOME ABERRATIONS; GENE EXPRESSION; HUMANS; IMMUNOPHENOTYPING; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, MYELOID, ACUTE;

EID: 84879387212     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.754096     Document Type: Article

References (12)

1. Topp MS, Kufer P, Gokbuget N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011;29:2493-2498.
2. Topp MS, Gokbuget N, Zugmaier G, et al. Long-term follow-up of hematological relapse-free survival in a phase 2 study of blinatumomab in patients with minimal residual disease (MRD) of B-precursor acute lymphoblastic leukemia (ALL). Blood 2012;120:5185-5187. Brentjens R
3. Y eh R, B ernal Y, et al. T reatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther 2010 ; 18:666-668.
4. Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptormodifi ed T cells in chronic lymphoid leukemia. N Engl J Med 2011 ; 365:725-733.
5. Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012; 119: 2709-2720.
6. B all E D, D avis R B, G riffin J D, et al. P rognostic value of lymphocyte surface markers in acute myeloid leukemia. Blood 1991;77:2242-2250.
7. Wetzler M, McElwain BK, Stewart CC, et al. HLA-DR antigen-negative acute myeloid leukemia. Leukemia 2003; 17: 707-715. (Pubitemid 36519367)
8. Lee J, Sait SN, Wetzler M. Characterization of dendritic-like cells derived from t(9;22) acute lymphoblastic leukemia blasts. Int Immunol 2004;16:1377-1389. (Pubitemid 39341551)
9. Gale RE, Linch DC. Clonality studies in acute myeloid leukemia. Leukemia 1998; 12: 117-120. (Pubitemid 28108060)
10. Notta F, Mullighan CG, Wang JC, et al. Evolution of human BCRABL1 lymphoblastic leukaemia-initiating cells. Nature 2011; 469: 362-367.
11. Schmitz M, Breithaupt P, Scheidegger N, et al. Xenografts of highly resistant leukemia recapitulate the clonal composition of the leukemogenic compartment. Blood 2011;118:1854-1864.
12. Stass S, Mirro J, Melvin S, et al. Lineage switch in acute leukemia. Blood 1984;64:701-706. (Pubitemid 14073491)